导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.29% | 2489/4773 |
| 近一周 | -2.59% | 4074/5465 |
| 近一月 | -7.16% | 4474/5421 |
| 近一季 | -14.28% | 4272/5231 |
| 近半年 | -2.64% | 2221/4920 |
| 近一年 | 1.93% | 2384/4394 |
| 近两年 | 63.11% | 1162/2954 |
| 近三年 | 34.90% | 912/2253 |
| 成立以来 | 69.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.80% 2489/4961 |
21.86% 1151/5312 |
- - |
- - |
| 2025 | 27.35% 1564/4813 |
-0.16% 2089/3635 |
-0.74% 3013/4076 |
31.27% 1127/4524 |
-2.11% 3093/4813 |
| 2024 | 14.84% 995/3463 |
0.60% 951/2808 |
-3.12% 1300/3014 |
21.31% 598/3129 |
-2.87% 2197/3463 |
| 2023 | -14.80% 1621/2656 |
4.78% 871/2280 |
-6.13% 1592/2385 |
-7.00% 1515/2515 |
-6.86% 1945/2655 |
| 2022 | -24.11% 1189/2207 |
-18.65% 1365/1919 |
9.73% 271/2016 |
-16.79% 1503/2113 |
2.17% 1022/2208 |
| 2021 | 5.95% 529/1822 |
-3.60% 816/1255 |
13.26% 293/1330 |
-6.52% 949/1466 |
3.81% 388/1822 |
| 2020 | 56.53% 140/1250 |
-5.73% 434/1028 |
22.80% 197/1067 |
12.67% 373/1164 |
20.01% 64/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商深证100ETF VS. 长安沪深300非周期A(740101) |